ReviewInternational journal of antimicrobial agents2016
Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet?
Review in International journal of antimicrobial agents, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 100 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
100 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- A Systematic Review of Pharmacokinetic Studies of Colistin and Polymyxin B in Adult Populations.Clinical pharmacokinetics · 2025Pooled it
- Efficacy and safety of different polymyxin-containing regimens for the treatment of pneumonia caused by multidrug-resistant gram-negative bacteria: a systematic review and network meta-analysis.Critical care (London, England) · 2024Pooled it
- Comparative Neurotoxicity of Polymyxin B and Colistin in Patients With Cancer.Pharmacotherapy · 2026Article
- Membrane Disruption and Charge Neutralization Drive Synergy Between LL37-Derived Peptides and Polymyxins AgainstBiomolecules · 2026Article
- Comparative efficacy and safety of colistin sulfate versus polymyxin B in critically ill patients with carbapenem-resistant gram-negative infections: a pilot inverse probability of treatment weighting-based retrospective cohort study.BMC infectious diseases · 2026Article
- Clinician decision-making for polymyxin dosing in critically ill patients with renal impairment: a qualitative study.Scientific reports · 2026Article
- Beyond β-Lactams: Defining the Role of Eravacycline in Multidrug-Resistant and Metallo-β-Lactamase-Producing Infections.Antibiotics (Basel, Switzerland) · 2026Review
- Temporin-GHa-derived peptides enhance the antibacterial and antibiofilm activities of polymyxin B against Pseudomonas aeruginosa and Escherichia coli.Archives of microbiology · 2026Article
- Commentary: Efficacy, safety, and therapeutic drug monitoring of polymyxin B sulfate and colistin sulfate in critically ill patients: a real-world retrospective study.Frontiers in pharmacology · 2026Article
- A Multi-Center Study of Population Pharmacokinetics of Polymyxin B in Critically Ill Patients.Drug design, development and therapy · 2026Article
- Polymyxin B-Associated Muscle Injury: A Case Report.Infection and drug resistance · 2026Article
- Genomic phylogeny, taxonomic classification, genetic landscape, and antibiotic resistance of clinicalFrontiers in microbiology · 2026Article
- A comparative study of intravenous polymyxin B and colistimethate sodium on efficacy, safety, and cost comparison in treating pulmonary infections: a retrospective cohort study.Frontiers in pharmacology · 2026Article
- Molecular mechanisms attributed to colistin renal proximal tubular epithelial cytotoxicity.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2025Review
- Article
- A novel role for colistin as an efflux pump inhibitor in multidrug-resistant Klebsiella pneumoniae.Scientific reports · 2025Article
- Challenges in the management of multidrug-resistant Gram-negative bacterial meningitis in children: a decade of clinical insights.BMC pediatrics · 2025Article
- Intravenous combined with nebulized polymyxin B may be effective in treating carbapenem-resistant gram-negative bacilli hospital-acquired pneumonia: a retrospective cohort study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Article
- Multidrug-Resistant Infections and Metabolic Syndrome: An Overlooked Bidirectional Relationship.Biomedicines · 2025Review
- Amphiphilic mPEG-PLGA copolymer nanoparticles co-delivering colistin and niclosamide to treat colistin-resistant Gram-negative bacteria infections.Communications biology · 2025Article
40 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The polymyxin antibiotics [colistin and polymyxin B (PMB)] are increasingly used as a last-line option for the treatment of infections caused by extensively drug-resistant Gram-negative bacteria. Despite having similar structures and antibacterial activity in vitro, the two clinically available polymyxins have very different pharmacological properties, as colistin (polymyxin E) is intravenously administered to patients in the form of an inactive prodrug colistin methanesulphonate (sodium). This review will discuss recent progress in the pharmacokinetics/pharmacodynamics and toxicity of colistin and PMB, the factors that affect their pharmacological profiles, and the challenges for the effective use of both polymyxins. Strategies are proposed for optimising their clinical utility based upon the recent pharmacological studies in vitro, in animals and patients. In the 'Bad Bugs, No Drugs' era, polymyxins are a critically important component of the antibiotic armamentarium against difficult-to-treat Gram-negative 'superbugs'. Rational approaches to the use of polymyxins must be pursued to increase their effectiveness and to minimise resistance and toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.